KD014
Based on 1 Customer Validation
KD014 (DX-2400) is a human monoclonal antibody that selectively targets MMP‑14. KD014 inhibits collagen degradation and regulates the polarization of macrophages toward an anti-inflammatory/anti-tumor phenotype. KD014 alleviates joint damage in rheumatoid arthritis and suppresses tumor growth and invasion. KD014 can be used in studies related to breast cancer and rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.98%
- Masse moléculaire:144.01 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
|
MMP14 0.9 nM (Ki) |
KD014 (0.1-50 μg/mL; 3 days) has no effect on the viability of 4T1 or E0771 mouse breast cancer cells[1].
KD014 (0.2-100 μg/mL) significantly inhibits the invasive ability of 4T1 mouse breast cancer cells through type I collagen matrix in a dose-dependent manner[1].
KD014 (100-500 nM; 4 days) dose-dependently inhibits the degradation of collagen membranes by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)[2].
KD014 (100-500 nM; 4 weeks) dose-dependently inhibits the invasion of bovine nasal cartilage by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4T1 murine breast carcinoma cells
-
Concentration:0.2, 2.0, 20, 100 μg/mL
-
Incubation Time:/
-
Result:Inhibited 4T1 cell invasion through a collagen matrix in a dose-dependent manner.
Exhibited statistically significant inhibition at all tested concentrations (P = .0314 at 0.2 μg/mL to P = .0004 at 100 μg/mL).
-
Cell Line:human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS)
-
Concentration:100 nM; 500 nM
-
Incubation Time:4 weeks
-
Result:Inhibited the invasion of human RA FLS into bovine nasal cartilage explants in a dose-dependent manner, as shown by reduced presence of invading cells compared to control.
KD014 (20-40 mg/kg; i.p.; once every other day for 10 days) significantly inhibits articular cartilage degradation and blocks arthritis progression in a mouse collagen-induced arthritis model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude mice (female, 6-8 weeks, orthotopic 4T1/E0771 breast cancer model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 48 hours; up to 10 injections
-
Result:Inhibited tumor growth.
Polarized macrophages to an antitumor M1‑like phenotype, elevated iNOS expression and tumor perfusion.
Reduced hypoxia, and synergizes with radiotherapy in murine orthotopic 4T1 and E0771 breast cancer models.
-
Animal Model:DBA/1 (male, 11-13 weeks old, collagen-induced arthritis model)[2]
-
Dosage:20, 40 mg/kg
-
Administration:i.p.; every other day; 10 days
-
Result:Markedly reduced cartilage degradation and serum COMP levels, mitigated arthritis spread to unaffected joints, and had minimal effect on joint swelling and bone erosion.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 NIH-3T3 cells labeling MMP14 with KD014 (HY-P991316, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 144.01 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
DX-2400; DX-2410
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Ager EI, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015;107(4):djv017. Published 2015 Feb 20. [Content Brief]
[2]. Kaneko K, et al. Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade. Arthritis Rheumatol. 2016 Feb;68(2):521-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KD014 Related Classifications
Cat. No.: HY-P991316
Powered by Bioz
- KD014
- DX-2400
- DX-2410
- KD 014
- KD-014
- DX2400
- DX 2400
- DX2410
- DX 2410
- DX-2410
- MMP
- NO Synthase
- rheumatoid arthritis fibroblast-like synoviocytes
- iNOS
- tumor-associated macrophage
- TGFβ
- transforming growth factor β
- orthotopic murine breast tumor models
- inducible nitric oxide synthase
- MMP14/MT1-MMP
- SMAD2/3
- matrix metalloproteinase 14
- Inhibitor
- inhibitor
- inhibit